Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05621226 · ClinicalTrials.gov registry record · NA
Message Communicating Latest Data on COVID-19 Transmission in Patient's Area
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 520,000
- Enrollment target
NCT05621226: Completed NA study, sponsored by University of Pennsylvania.
NCT05621226 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 520,000 participants, above the 1,395-participant average among 58,714 other NA trials with a reported enrollment target (37176% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05621226, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 520,000 participants
- Enrollment target
Study Summary
This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned. The focal comparison in this experiment is between a message encouraging vaccination by communicating to patients that they live in an area with significant COVID transmission and a control message telling patients that an updated COVID booster vaccine is waiting for them.
Primary Outcome
Whether patients receive a bivalent COVID booster at the pharmacy in question
Interventions
- BEHAVIORAL COVID Booster text messages
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520,000 participants |
| Start Date | 2022-11-03 |
| Est. Completion | 2023-02-06 |
| Phase | NA |
What the finished NCT05621226 record still lists
NCT05621226 is an interventional study that assigns participants to a tested intervention. Its 520,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,395-participant average among 58,714 other NA trials with a reported enrollment target (37176% higher).
The record links to 0 conditions, and to 1 intervention - of which COVID Booster text messages is the first listed.
NCT05621226 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05621226 about?
NCT05621226 is a clinical study titled "Message Communicating Latest Data on COVID-19 Transmission in Patient's Area". This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned. The focal comparison in this experiment is between a message encouraging vaccination by communicating to patients that they live in an area ...
What is the current status of trial NCT05621226?
This trial is currently completed. It is a NA study. The enrollment target is 520,000 participants. The study started on 2022-11-03. Estimated completion is 2023-02-06.
What interventions are being tested in trial NCT05621226?
The interventions under investigation include: COVID Booster text messages (BEHAVIORAL).
Who is sponsoring clinical trial NCT05621226?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05621226's enrollment target sits among peer trials
520,000 1st of 2000 higher than 2,000 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05065060 · 500,000 participants
Parkinson Progression Marker Initiative Online (PPMI Online)
- NCT06017687 · 500,000 participants · NA
Data Collection and Evaluation of OptiBP Under Investigational Use
- NCT06342375 · 425,000 participants · NA
Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage
- NCT06934239 · 400,000 participants · Phase 4
A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI